OTC Obesity - Poland

April 2010 | 35 pages | ID: OB22C83517AEN
Euromonitor International Ltd

Abstracts

2009 was the first year that OTC obesity gained a presence in Poland. In April 2009 GlaxoSmithKline Pharmaceuticals SA launched the first orlistat-based OTC obesity product under the Alli brand name. 2009 value sales reached more than PLN4 million.

Euromonitor International's OTC Obesity Products in Poland report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Consumer Health industry;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

Executive Summary
Continued Sales Growth Despite Economic Slowdown
Poles Becoming Increasingly Health-conscious
Multinational Companies Prove Strong Opponents
Chemists/pharmacies Remains Core Distribution Channel
Further Growth in Consumer Healthcare Expected
Key Trends and Developments
Health and Wellness Trend Boosts Sales
Lifestyle Changes Shape Consumer Behaviour
Growing Focus on Looking Good Shapes Sales
Domestic Companies Fight Back
Targeted Product Developments Fuel Growth
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Life Expectancy at Birth 2004-2009
Market Data
  Table 3 Sales of Consumer Health by Sector: Value 2004-2009
  Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 5 Consumer Health Company Shares by Value 2005-2009
  Table 6 Consumer Health Brand Shares by Value 2006-2009
  Table 7 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 8 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 9 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 10 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
  Summary 1 OTC Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
  Summary 2 Research Sources
Apipol-farma Sp Zoo
Strategic Direction
Key Facts
  Summary 3 Apipol-Farma Sp zoo: Key Facts
  Summary 4 Apipol-Farma Sp zoo: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 5 Apipol-Farma Sp zoo: Competitive Position 2009
Herbapol Lublin SA
Strategic Direction
Key Facts
  Summary 6 Herbapol Lublin SA: Key Facts
  Summary 7 Herbapol Lublin SA: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 8 Herbapol Lublin SA: Competitive Position 2009
Polpharma SA
Strategic Direction
Key Facts
  Summary 9 Polpharma SA: Key Facts
  Summary 10 Polpharma SA: Operational Indicators
Company Background
Production
  Summary 11 Polpharma SA: Production Statistics 2009
Competitive Positioning
  Summary 12 Polpharma SA: Competitive Position 2009
Polski Lek SA
Strategic Direction
Key Facts
  Summary 13 Polski Lek SA: Key Facts
Company Background
Production
Competitive Positioning
  Summary 14 Polski Lek SA: Competitive Position 2009
Ppf Hasco-lek SA
Strategic Direction
Key Facts
  Summary 15 PPF Hasco-Lek SA: Key Facts
  Summary 16 PPF Hasco-Lek SA: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 17 PPF Hasco-Lek SA: Competitive Position 2009
Trends
Category Data
  Table 11 Sales of OTC Obesity: Value 2009
  Table 12 OTC Obesity Company Shares by Value 2005-2009
  Table 13 OTC Obesity Brand Shares by Value 2006-2009
  Table 14 Forecast Sales of OTC Obesity: Value 2009-2014
  Table 15 Forecast Sales of OTC Obesity: % Value Growth 2009-2014